B7

Biotin Water® Hair, Skin, & Nails Makes Its Way To Publix Supermarkets

Friday, June 11, 2021 - 1:44pm

ROME, Ga., June 11, 2021 /PRNewswire/ --2T Water, LLC, the maker of Biotin Water Hair, Skin, and Nails announced today that Biotin Water will be sold at Publix Supermarkets across the southeast region of the United States starting June 2021.

Key Points: 
  • ROME, Ga., June 11, 2021 /PRNewswire/ --2T Water, LLC, the maker of Biotin Water Hair, Skin, and Nails announced today that Biotin Water will be sold at Publix Supermarkets across the southeast region of the United States starting June 2021.
  • 2T Water, LLC owns the exclusive rights to distribute Biotin Water Hair, Skin, and Nails which is the first biotin infused beverage that delivers 300 mcg per 16oz with zinc and folic acid included in the proprietary formula.
  • Biotin Water Hair, Skin, and Nails is formulated to ensure the body is properly hydrated while enjoying the many benefits of B7, often considered the most overlooked vitamin.
  • This new introduction of Biotin Water gives consumers more locations throughout the southeast to purchase Biotin Water in a great grocery chain.

Y-mAbs Enters into Exclusive Distribution Agreement with Adium Pharma S.A. for DANYELZA® (naxitamab-gqgk) and Omburtamab in Latin America

Wednesday, May 19, 2021 - 9:01pm

B7-H3 is an immune checkpoint molecule that is widely expressed in tumor cells of several cancer types.

Key Points: 
  • B7-H3 is an immune checkpoint molecule that is widely expressed in tumor cells of several cancer types.
  • Under the terms of the agreement, Adium will employ its sales and marketing expertise to distribute DANYELZA and omburtamab, if approved, in the territory.
  • In addition, Adium will submit registration files on behalf of the Company in certain parts of the territory.
  • Adium distributes its products in 18 Latin American & Caribbean countries including Brazil, Mexico and Colombia.

Mersana Therapeutics Presents Preclinical Data Highlighting Potential of XMT-2056 and XMT-1660 in Three Posters at Virtual 2021 AACR Annual Meeting

Saturday, April 10, 2021 - 2:00pm

We expect to complete IND-enabling studies and advance both XMT-1660 and XMT-2056 into the clinic in early 2022.

Key Points: 
  • We expect to complete IND-enabling studies and advance both XMT-1660 and XMT-2056 into the clinic in early 2022.
  • Details of the posters are as follows:
    These data show that B7-H4 is a promising target for a Dolasynthen ADC due to its expression and function.
  • B7-H4 is expressed across multiple different tumor types with high unmet medical need, including breast, endometrial and ovarian.
  • In the MX-1 triple-negative breast model, XMT-1660 showed complete, durable regressions of tumors at a DolaLock payload dose of 0.15 mg/kg.

Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2020 Financial Results and Business Updates

Friday, February 19, 2021 - 1:00pm

ET to report financial results for the fourth quarter and year ended December 31, 2020 and provide business updates.

Key Points: 
  • ET to report financial results for the fourth quarter and year ended December 31, 2020 and provide business updates.
  • To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 2354447.
  • A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com .
  • The Companys early-stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING-agonist ADC developed using the Companys Immunosynthen platform.

Mersana Therapeutics Announces Corporate and Pipeline Updates and 2021 Goals and Anticipated Milestones

Tuesday, January 5, 2021 - 3:00pm

The Company will also present preclinical data for XMT-1660, a first-in-class ADC targeting B7-H4, and outline the Companys goals and anticipated milestones for 2021.

Key Points: 
  • The Company will also present preclinical data for XMT-1660, a first-in-class ADC targeting B7-H4, and outline the Companys goals and anticipated milestones for 2021.
  • We will also work to advance XMT-1660, our first-in-class ADC targeting B7-H4, and XMT-2056, our first ImmunosynthenSTING-agonist ADC development candidate, through IND-enabling studies.
  • We believe this study design will allow for significant operational efficiencies and leverages continued momentum in patient enrollment.
  • A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at https://ir.mersana.com/events-and-presentations .

Mersana Therapeutics Reports Preclinical Data from Immunosynthen STING-Agonist ADC Platform and Pipeline

Wednesday, November 11, 2020 - 2:00pm

These data highlight the novel research undertaken by our scientists to elucidate the mechanism of activation of the STING pathway in the tumor.

Key Points: 
  • These data highlight the novel research undertaken by our scientists to elucidate the mechanism of activation of the STING pathway in the tumor.
  • Building on our expertise in ADC design and optimization, we have developed the Immunosynthen STING-Agonist ADC platform and have validated its potential across multiple targets, said Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics.
  • We look forward to providing a more thorough overview of the platform as well as our pipeline of Immunosynthen STING-agonist ADCs during our webinar on November 16, 2020.
  • The Companys early stage programs include a B7-H4 targeting ADC, as well as a STING-agonist ADC developed using the Companys Immunosynthen platform.

Mersana Therapeutics to Host Conference Call Announcing Third Quarter 2020 Financial Results and Business Updates

Monday, November 2, 2020 - 1:00pm

ET to report financial results for the third quarter ended September 30, 2020 and provide business updates.

Key Points: 
  • ET to report financial results for the third quarter ended September 30, 2020 and provide business updates.
  • To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 7953159.
  • A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com .
  • The Companys early stage programs include a B7-H4 targeting ADC, as well as a STING-agonist ADC developed using the Companys Immunosynthen platform.

Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2020 Financial Results and Business Updates

Friday, July 31, 2020 - 1:00pm

ET to report financial results for the second quarter ended June 30, 2020 and provide business updates.

Key Points: 
  • ET to report financial results for the second quarter ended June 30, 2020 and provide business updates.
  • To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 1081289.
  • A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com .
  • The Companys early stage programs include a B7-H4 targeting ADC, as well as a STING-agonist ADC developed using the Companys Immunosynthen platform.

Cue Biopharma Announces PLOS One Publication Demonstrating the Generation and Evaluation of Novel Molecules with Directed Mutations within the B7 Superfamily

Wednesday, July 8, 2020 - 1:00pm

In this work, researchers focused primarily on the recently described interaction between B7-1 and PD-L1, two molecules within the B7 superfamily, which are of critical importance for controlling anti-tumor immunity, autoimmunity and infectious diseases.

Key Points: 
  • In this work, researchers focused primarily on the recently described interaction between B7-1 and PD-L1, two molecules within the B7 superfamily, which are of critical importance for controlling anti-tumor immunity, autoimmunity and infectious diseases.
  • This approach augments and supplements Cue Biopharmas Immuno-STAT and Neo-STAT platforms, leveraging rational protein engineering to generate therapeutic frameworks possessing desirable drug properties while attenuating and/or abrogating unwanted, deleterious effects.
  • Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body to transform the treatment of cancer and autoimmune diseases.
  • Our actual results and financial condition may differ materially from those indicated in the forward-looking statements.

TCR² Therapeutics to Present Data on PD-1 Switch TRuC Enhancement at American Association for Cancer Research (AACR) Virtual Meeting 2020

Friday, May 15, 2020 - 1:30pm

The e-poster presentation will highlight preclinical data of the Companys proprietary T Cell Receptor Fusion Construct (TRuC) T cells that co-express a PD-1:CD28 switch receptor, which acts as a cell-intrinsic mechanism to overcome PD-L1/PD-L2 mediated immunosuppression.

Key Points: 
  • The e-poster presentation will highlight preclinical data of the Companys proprietary T Cell Receptor Fusion Construct (TRuC) T cells that co-express a PD-1:CD28 switch receptor, which acts as a cell-intrinsic mechanism to overcome PD-L1/PD-L2 mediated immunosuppression.
  • Upon repeated antigen stimulation, co-expression of the switch receptor in mesothelin-targeting TC-210 T cells enhanced TCR downstream signaling, prevented PD-L1-mediatied functional T-cell inhibition, significantly increased proliferation and augmented the production of growth and effector cytokines.
  • In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while exhibiting lower levels of cytokine release.
  • Any forward-looking statement included in this press release speaks only as of the date on which it was made.